{"id":11637,"date":"2026-08-04T21:02:07","date_gmt":"2026-08-04T19:02:07","guid":{"rendered":"https:\/\/anale.steconomiceuoradea.ro\/en\/?p=11637"},"modified":"2026-08-04T21:02:07","modified_gmt":"2026-08-04T19:02:07","slug":"early-mover-advantage-versus-second-takes-most-dynamics-of-the-global-obesity-treating-sector","status":"publish","type":"post","link":"https:\/\/anale.steconomiceuoradea.ro\/en\/2026\/08\/04\/early-mover-advantage-versus-second-takes-most-dynamics-of-the-global-obesity-treating-sector\/","title":{"rendered":"\u201cEARLY-MOVER ADVANTAGE\u201d VERSUS \u201cSECOND TAKES MOST\u201d DYNAMICS OF THE GLOBAL OBESITY-TREATING SECTOR"},"content":{"rendered":"<p><strong>\u201cEARLY-MOVER ADVANTAGE\u201d VERSUS \u201cSECOND TAKES MOST\u201d DYNAMICS OF THE GLOBAL OBESITY-TREATING SECTOR<\/strong><\/p>\n<p>Adrian NEGREA, Daniel-Nicu IONA\u0218<\/p>\n<p><em>Department of International Business, Faculty of Economics, University of Oradea, Oradea, Romania<\/em><\/p>\n<p><em><u>ngr_adrian@yahoo.com<\/u><\/em><\/p>\n<p><em><u>ionasdanieln@gmail.com<\/u><\/em><\/p>\n<p><strong><em>Abstract: <\/em><\/strong><em>The pharmaceutical landscape for obesity treatments is defined by extreme market volatility and risks, where clinical trial data and regulatory milestones serve as the primary catalysts for multi-billion dollar shifts in valuation. Recent market shifts illustrate a transition from early-mover advantages to a regime dictated by clinical superiority and manufacturing scale, as evidenced by Eli Lilly surpassing Novo Nordisk in market capitalization; while analysis of various market scenarios reveals that while positive Phase 2\/3 data can double the value of clinical-stage companies, established leaders face significant risks from &#8220;multiple compression,&#8221; competitive displacement, and the emergence of lower-priced copycat medications. Furthermore, a strategic focus on the GLP-1\/GIP receptor space is currently rewarded with valuation premiums; while resource diversification often leads to institutional divestment and stagnant growth; which sometimes can lead to market loss.<\/em><\/p>\n<p><strong><em>Keywords: <\/em><\/strong><em>Obesity Therapeutics; GLP-1\/GIP; Pharmaceutical Valuation; Clinical Trial Catalysts; Market Capitalization; Competitive Displacement; Multiple Compression.<\/em><\/p>\n<p><strong><em>JEL Classification: <\/em><\/strong><em>L65; G14; O32; L11.<\/em><\/p>\n<p><a href=\"https:\/\/anale.steconomiceuoradea.ro\/en\/wp-content\/uploads\/2026\/08\/21_Negrea.pdf\">Download article<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u201cEARLY-MOVER ADVANTAGE\u201d VERSUS \u201cSECOND TAKES MOST\u201d DYNAMICS OF THE GLOBAL OBESITY-TREATING SECTOR Adrian NEGREA, Daniel-Nicu IONA\u0218 Department of International Business, Faculty of Economics, University of Oradea, Oradea, Romania ngr_adrian@yahoo.com ionasdanieln@gmail.com Abstract: The pharmaceutical landscape for obesity treatments is defined by extreme market volatility and risks, where clinical trial data and regulatory milestones serve as the [&hellip;]<\/p>\n","protected":false},"author":123465,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"ngg_post_thumbnail":0,"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","jetpack_publicize_message":"","jetpack_is_tweetstorm":false,"jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","enabled":false}}},"categories":[18],"tags":[],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_shortlink":"https:\/\/wp.me\/p3c4cf-31H","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/anale.steconomiceuoradea.ro\/en\/wp-json\/wp\/v2\/posts\/11637"}],"collection":[{"href":"https:\/\/anale.steconomiceuoradea.ro\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/anale.steconomiceuoradea.ro\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/anale.steconomiceuoradea.ro\/en\/wp-json\/wp\/v2\/users\/123465"}],"replies":[{"embeddable":true,"href":"https:\/\/anale.steconomiceuoradea.ro\/en\/wp-json\/wp\/v2\/comments?post=11637"}],"version-history":[{"count":1,"href":"https:\/\/anale.steconomiceuoradea.ro\/en\/wp-json\/wp\/v2\/posts\/11637\/revisions"}],"predecessor-version":[{"id":11644,"href":"https:\/\/anale.steconomiceuoradea.ro\/en\/wp-json\/wp\/v2\/posts\/11637\/revisions\/11644"}],"wp:attachment":[{"href":"https:\/\/anale.steconomiceuoradea.ro\/en\/wp-json\/wp\/v2\/media?parent=11637"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/anale.steconomiceuoradea.ro\/en\/wp-json\/wp\/v2\/categories?post=11637"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/anale.steconomiceuoradea.ro\/en\/wp-json\/wp\/v2\/tags?post=11637"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}